📰 Libretto 431 News
Libretto 431 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Libretto 431. Real-time updates on events, politics, business and more.
November 17, 2023
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
November 10, 2023
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
August 17, 2023
Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.